Critical To Treat Comorbidities That Worsen Course of Multiple Sclerosis

MedicalResearch.com Interview with:
Jorge Correale MD

Department of Neurology, Institute for Neurological Research Dr Raúl Carrea
Buenos Aires, Argentina

MedicalResearch.com: What is the background for this study? What are the main findings?

Dr. Correale: First it is now well known that in parallel to the specific treatment of Multiple Sclerosis, those comorbidities that worsen the course of the disease should be treated. For example, cardiovascular diseases. Moreover there are in vitro and in animal models evidence of an anti-inflammatory role of compounds investigated in this publication evidence.

MedicalResearch.com: What should clinicians and patients take away from your report?

Dr. Correale: The main point aims not to use these drugs as a new treatment for Multiple Sclerosis, which require further studies, but the treatment of any co-morbidity disease associated with MS.

Many epidemiological studies support the idea that many of them worsen the course of the disease.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Dr. Correale: The impact of these drugs on NMR parameters and background in animal models, may justify its future exploration as agents to join the armamentarium of treatments for the control of  Multiple Sclerosis. Unfortunately, the number of patients included in this study does not allow to draw conclusions about its clinical relevance, and therefore if this option is decided should be considered studies with larger numbers of patients. Moreover, given their metabolic effects, probably the population must be very clearly selected to avoid undesirable metabolic side effects affecting the patient’s health.

Once again the critical point of this work is to demonstrate that any comorbidity associated with Multiple Sclerosis should be treated.

MedicalResearch.com: Is there anything else you would like to add?

Dr. Correale: MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

Negrotto L, Farez MF, Correale J. Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. JAMA Neurol. Published online March 07, 2016. doi:10.1001/jamaneurol.2015.4807.

 

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

 

Jorge Correale MD (2016). Critical To Treat Comorbidities That Worsen Course of Multiple Sclerosis 

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.